MNKD Q4 2022 Earnings — MannKind Corporation Revenue & Financial Results | Market Cap Arena

MNKDMannKind Corporation

$813M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$36M+188.1% YoY

Gross Profit

$20M55.3% margin

Operating Income

-$13M-35.5% margin

Net Income

-$18M-49.8% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+9.9%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$7M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$295M

Total Liabilities

$546M

Stockholders' Equity

-$251M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$36M	$13M	+188.1%
Gross Profit	$20M	$1M	+1744.1%
Operating Income	-$13M	-$24M	+46.6%
Net Income	-$18M	-$28M	+36.0%

Revenue Segments

Product Sales

$26M49%

Product

$17M33%

Royalty

$9M17%

Service

$513,0001%